Loading company…
Visus Therapeutics develops pharmaceutical treatments for eye conditions, including presbyopia.
Founded in 2019 by Benjamin Bergo, Visus Therapeutics develops treatments for eye conditions, including VTI-001 (BRIMOCHOL™), a daily eye drop candidate for presbyopia, and VTI-003. The company has offices in Seattle, Washington, and Orange County, California. In August 2021, it raised USD 20 million in venture funding led by Life Sciences Partners, Sage Partners, and Johnson & Johnson Innovation.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in